# ARS Pharmaceuticals, Inc.: overview SPRY · Nasdaq · CIK 1671858 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/spry.md) · [Financials](/companies/spry/financials.md) · [Filings](/companies/spry/filings.md) · [Insiders](/companies/spry/insiders.md) Latest reported revenue: [$33.7m](/filings/0001193125-26-349140.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-349140). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2.1](/filings/0001193125-25-273111.md) | [86.6 d](/filings/0001193125-26-097478.md) | [8.0](/filings/0001193125-26-225142.md) | [15.7](/filings/0001193125-26-349140.md) | [32.5](/filings/0001193125-25-273111.md) | [28.1 d](/filings/0001193125-26-097478.md) | [22.7](/filings/0001193125-26-225142.md) | [33.7](/filings/0001193125-26-349140.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1051.6%)](/filings/0001193125-25-273111.md) | [54.5% d](/filings/0001193125-26-097478.md) | [(466.3%)](/filings/0001193125-26-225142.md) | [(302.9%)](/filings/0001193125-26-349140.md) | [(163.7%)](/filings/0001193125-25-273111.md) | [(147.6%) d](/filings/0001193125-26-097478.md) | [(265.2%)](/filings/0001193125-26-225142.md) | [(182.6%)](/filings/0001193125-26-349140.md) | | Net margin | % | [(925.0%)](/filings/0001193125-25-273111.md) | [57.7% d](/filings/0001193125-26-097478.md) | [(425.7%)](/filings/0001193125-26-225142.md) | [(285.6%)](/filings/0001193125-26-349140.md) | [(157.4%)](/filings/0001193125-25-273111.md) | [(147.1%) d](/filings/0001193125-26-097478.md) | [(267.3%)](/filings/0001193125-26-225142.md) | [(185.2%)](/filings/0001193125-26-349140.md) | | Diluted EPS | $ per share | [(0.20)](/filings/0001193125-25-273111.md) | not reported | [(0.35)](/filings/0001193125-26-225142.md) | [(0.46)](/filings/0001193125-26-349140.md) | [(0.52)](/filings/0001193125-25-273111.md) | not reported | [(0.61)](/filings/0001193125-26-225142.md) | [(0.63)](/filings/0001193125-26-349140.md) | | Free cash flow | $m | [(14.6) d](/filings/0001193125-25-273111.md) | [41.7 d](/filings/0001193125-26-097478.md) | [(40.8)](/filings/0001193125-26-225142.md) | [(39.6) d](/filings/0001193125-26-349140.md) | [(47.2) d](/filings/0001193125-25-273111.md) | [(43.5) d](/filings/0001193125-26-097478.md) | [(44.9)](/filings/0001193125-26-225142.md) | [(60.9) d](/filings/0001193125-26-349140.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [5.5](/filings/0000950170-23-009491.md) | [1.3](/filings/0000950170-24-034689.md) | [0.0](/filings/0000950170-25-042320.md) | [89.1](/filings/0001193125-26-097478.md) | [84.3](/filings/0001193125-26-097478.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(353.3%)](/filings/0000950170-23-009491.md) | [(2698.8%)](/filings/0000950170-24-034689.md) | [(225066.7%)](/filings/0000950170-25-042320.md) | [(3.5%)](/filings/0001193125-26-097478.md) | [(212.9%)](/filings/0001193125-26-097478.md) | | Net margin | % | [(367.7%)](/filings/0000950170-23-009491.md) | [(2635.4%)](/filings/0000950170-24-034689.md) | [(181216.7%)](/filings/0000950170-25-042320.md) | [9.0%](/filings/0001193125-26-097478.md) | [(203.3%)](/filings/0001193125-26-097478.md) | | Diluted EPS | $ per share | [(0.70)](/filings/0000950170-23-009491.md) | [(0.87)](/filings/0000950170-24-034689.md) | [(0.57)](/filings/0000950170-25-042320.md) | [0.08](/filings/0001193125-26-097478.md) | [(1.74)](/filings/0001193125-26-097478.md) | | Free cash flow | $m | [(17.6)](/filings/0000950170-23-009491.md) | [(40.3)](/filings/0000950170-24-034689.md) | [(59.4)](/filings/0000950170-25-042320.md) | [13.0](/filings/0001193125-26-097478.md) | [(171)](/filings/0001193125-26-097478.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/spry/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $87.0m | 10,860,977 | | Unchanged | | [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $68.4m | 8,540,861 | | Added +540,861 | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $66.4m | 8,288,510 | | Unchanged | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $60.1m | 7,503,812 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $42.5m | 5,311,319 | | Added +299,065 | | [Tyro Capital Management LLC](/funds/1915395.md) | 2026-06-30 | $35.7m | 4,459,337 | | Added +1,490,738 | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $33.4m | 4,170,629 | | Added +57,012 | | [SR One Capital Management, LP](/funds/1910264.md) | 2026-06-30 | $32.1m | 4,012,903 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $29.9m | 3,730,623 | | Added +85,657 | | [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $22.1m | 2,754,931 | | New +2,754,931 | ## Recent filings [All 541 filings](/companies/spry/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 20:05 ET | [10-Q](/filings/0001193125-26-349140.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349140 | | 2026-08-13 | 20:03 ET | [8-K](/filings/0001193125-26-349127.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349127 | | 2026-07-17 | 20:02 ET | [8-K](/filings/0001193125-26-307773.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-307773 | | 2026-07-07 | 20:38 ET | [8-K](/filings/0001193125-26-297554.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-297554 | | 2026-06-25 | 21:01 ET | [8-K](/filings/0001193125-26-282994.md) | 5.07 Shareholder vote results | 0001193125-26-282994 | | 2026-05-15 | 10:17 ET | [10-Q](/filings/0001193125-26-225142.md) | Quarterly report, period 2026-03-31 | 0001193125-26-225142 | | 2026-05-15 | 10:02 ET | [8-K](/filings/0001193125-26-225055.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-225055 | | 2026-05-13 | 12:15 ET | [8-K](/filings/0001193125-26-220671.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-220671 | | 2026-04-29 | 20:00 ET | [DEF 14A](/filings/0001193125-26-191433.md) | Proxy statement, period 2026-06-24 | 0001193125-26-191433 | | 2026-03-09 | 10:07 ET | [10-K](/filings/0001193125-26-097478.md) | Annual report, period 2025-12-31 | 0001193125-26-097478 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-097478.md), filed Mar 9, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/705c135f-e1d2-4c30-88c1-66596f21edbc) ## About the filer - CIK: 1671858 - Tickers: SPRY - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.